Hansa Biopharma AB (OSTO:HNSA) Institutional Ownership : 4.15% (As of May. 31, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hansa Biopharma AB's institutional ownership is 4.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hansa Biopharma AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hansa Biopharma AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Hansa Biopharma AB Institutional Ownership Historical Data

The historical data trend for Hansa Biopharma AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Institutional Ownership Chart

Hansa Biopharma AB Historical Data

The historical data trend for Hansa Biopharma AB can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30
Institutional Ownership	6.12	6.13	4.88	4.67	4.77	4.85	4.82	4.84	4.81	4.14

Hansa Biopharma AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines